• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
    • {%itemName%} {%arrowSpan%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Identifying Patients and Referral

      Are all people with complex/advanced Parkinson's being identified appropriately?1,2

      *HES is a database of administrative healthcare data maintained by NHS Digital. The data in this reference were collected between 2013 and 2018.

      Hospital episode statistics data for complex/advanced PD patients4

      PD, Parkinson's disease; pts, patients.

      A large proportion of older complex/advanced PD patients aren't receiving advanced therapy4

      Breakdown of patients by age4


      Breakdown of patients by region4

      There are still many patients who are eligible to receive advanced therapies but are not receiving advanced treatment. Most of the untreated advanced PD patients are >70 years old.4


      Patient video: Ian's story   



      "I don't do a lot of walking until I put my pump on at, normally, about half-past eight. Even the dog looks at me strange..."


      Ian, 2019. Duodopa patient



      When is the best time to consider people with Parkinson’s for an advanced treatment?

      As Parkinson's progresses, worsening gastric transit may lead to increased frequency of oral levodopa to try to manage symptoms.6

      Complex Parkinson's Assessment Tool

      The Complex Parkinson’s Assessment Tool has been developed for UK healthcare professionals by a working group of UK neurology specialists in collaboration with AbbVie to apply the findings from the Delphi consensus.7

      It can be used to identify Parkinson’s patients whose oral dopaminergic therapies may no longer be adequately controlling their symptoms. These patients may therefore benefit from referral to a specialist centre for non-oral therapies.

      The tool was developed in collaboration with Dr Konrad Szewczyk-Krolikowski, Dr Jonathan Evans, Dr Nirosen Vijiaratnam, Dr Vaclav Dostal, Lynne Osborne, Alison Leake, Miriam Parry, Patsy Cotton, Tracy McElwaine and Jane Alty.



      1.  Odin P, et al. Parkinsonism Relat Disord 2015;21:1133–44.
      2.  Worth PF. Pract Neurol 2013;13:140–52.
      3.  Parkinson’s UK. Media and Press Office. Available at: https://www.parkinsons.org.uk/about-us/media-and-press-office. Accessed March 2021.
      4.  AbbVie Ltd. Data on File. REF-37728.
      5.  Parkinson's UK. The Incidence and Prevalence of Parkinson’s in the UK (2017). Available at:
         https://www.parkinsons.org.uk/sites/default/files/2018-01/Prevalence%20%20Incidence%20Report%20Latest_Public_2.pdf. Accessed: May 2019.
      6.  Varanese S, et al. Parkinsons Dis 2010;2010:480260.
      7.  Antonini A, et al. Curr Med Res Opin 2018;34:2063–73.


      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.

      Adverse events should also be reported to AbbVie on GBPV@abbvie.com 


      UK-DUOD-210078. Date of preparation: May 2021.